Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more
Nanobiotix (NBTX) - Net Assets
Latest net assets as of June 2025: $-68.95 Million USD
Based on the latest financial reports, Nanobiotix (NBTX) has net assets worth $-68.95 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($45.17 Million) and total liabilities ($114.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-68.95 Million |
| % of Total Assets | -152.64% |
| Annual Growth Rate | N/A |
| 5-Year Change | -193.24% |
| 10-Year Change | -520.87% |
| Growth Volatility | 413.06 |
Nanobiotix - Net Assets Trend (2011–2024)
This chart illustrates how Nanobiotix's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nanobiotix (2011–2024)
The table below shows the annual net assets of Nanobiotix from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-65.70 Million | -3463.07% |
| 2023-12-31 | $-1.84 Million | +93.18% |
| 2022-12-31 | $-27.05 Million | -200.95% |
| 2021-12-31 | $26.79 Million | -61.98% |
| 2020-12-31 | $70.47 Million | +3791.36% |
| 2019-12-31 | $-1.91 Million | -113.40% |
| 2018-12-31 | $14.24 Million | -67.57% |
| 2017-12-31 | $43.92 Million | +152.45% |
| 2016-12-31 | $17.40 Million | +11.45% |
| 2015-12-31 | $15.61 Million | -48.50% |
| 2014-12-31 | $30.32 Million | +852.78% |
| 2013-12-31 | $3.18 Million | -70.25% |
| 2012-12-31 | $10.70 Million | +1055.72% |
| 2011-12-31 | $925.53K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nanobiotix's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6288542200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.42 Million | % |
| Other Comprehensive Income | $-311.51 Million | % |
| Other Components | $312.51 Million | % |
| Total Equity | $-65.70 Million | 100.00% |
Nanobiotix Competitors by Market Cap
The table below lists competitors of Nanobiotix ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DEVELIA S.A. INH. ZY 1
F:94L
|
$991.94 Million |
|
GRUPO ELEKTRA (GE7C.SG)
STU:GE7C
|
$992.38 Million |
|
Ganzhou Tengyuan Cobalt New Material Co. Ltd.
SHE:301219
|
$992.48 Million |
|
China Southern Power Grid Energy Efficiency & Clean Energy Co Ltd
SHE:003035
|
$992.73 Million |
|
Corvus Pharmaceuticals Inc
NASDAQ:CRVS
|
$991.72 Million |
|
Trupanion Inc
NASDAQ:TRUP
|
$991.05 Million |
|
Khang Dien House Trading and Investment JSC
VN:KDH
|
$991.00 Million |
|
The First Bancshares, Inc.
NASDAQ:FBMS
|
$990.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanobiotix's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,844,000 to -65,703,000, a change of -63,859,000.
- Net loss of 68,132,000 reduced equity.
- Other comprehensive income decreased equity by 35,437,000.
- Other factors increased equity by 39,710,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-68.13 Million | -103.7% |
| Other Comprehensive Income | $-35.44 Million | -53.94% |
| Other Changes | $39.71 Million | +60.44% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Nanobiotix's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.60 | $32.08 | x |
| 2012-12-31 | $1.30 | $32.08 | x |
| 2013-12-31 | $0.30 | $32.08 | x |
| 2014-12-31 | $2.36 | $32.08 | x |
| 2015-12-31 | $1.10 | $32.08 | x |
| 2016-12-31 | $1.14 | $32.08 | x |
| 2017-12-31 | $2.51 | $32.08 | x |
| 2018-12-31 | $0.73 | $32.08 | x |
| 2019-12-31 | $-0.09 | $32.08 | x |
| 2020-12-31 | $2.89 | $32.08 | x |
| 2021-12-31 | $0.77 | $32.08 | x |
| 2022-12-31 | $-0.78 | $32.08 | x |
| 2023-12-31 | $-0.05 | $32.08 | x |
| 2024-12-31 | $-1.39 | $32.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanobiotix utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: -0.17x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-116.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -566.87% | -385.69% | 0.47x | 3.15x | $-5.34 Million |
| 2012 | -49.84% | -7189.05% | 0.01x | 1.31x | $-6.40 Million |
| 2013 | -255.99% | -4404.14% | 0.02x | 2.34x | $-8.46 Million |
| 2014 | -31.52% | -987.75% | 0.03x | 1.22x | $-12.59 Million |
| 2015 | -108.92% | -6403.14% | 0.01x | 1.69x | $-18.56 Million |
| 2016 | -125.76% | -1404.31% | 0.05x | 1.75x | $-23.62 Million |
| 2017 | -59.52% | -10375.62% | 0.00x | 1.31x | $-30.54 Million |
| 2018 | -209.90% | -25772.41% | 0.00x | 3.24x | $-31.32 Million |
| 2019 | 0.00% | -74875.00% | 0.00x | 0.00x | $-50.72 Million |
| 2020 | -47.71% | -67246.00% | 0.00x | 1.90x | $-40.67 Million |
| 2021 | -175.45% | -1775.75% | 0.03x | 3.80x | $-49.68 Million |
| 2022 | 0.00% | -1194.37% | 0.08x | 0.00x | $-54.34 Million |
| 2023 | 0.00% | -109.64% | 0.39x | 0.00x | $-39.52 Million |
| 2024 | 0.00% | 0.00% | -0.17x | 0.00x | $-61.56 Million |
Industry Comparison
This section compares Nanobiotix's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanobiotix (NBTX) | $-68.95 Million | -566.87% | N/A | $991.81 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |